Philippines - English - FDA (Food And Drug Administration)

euro-health care exponents, inc; importer: n/a; distributor: nutramedica inc. - ascorbic acid , zinc , cholecalciferol (vitamin d3) - 500 mg (equivalent to 562.43 mg sodium ascorbate)/10 mg (equivalent to 70 mg zinc gluconate)/1,000 iu per capsule

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - zinc oxide - cutaneous ointment - 150mg/1gram

Philippines - English - FDA (Food And Drug Administration)

euro-healthcare exponents, inc.; distributor: medhaus pharma, inc. - ranitidine (as hydrochloride) - solution for injection - 25 mg/ml (50 mg/2 ml)

Philippines - English - FDA (Food And Drug Administration)

euro-healthcare exponents, inc.; distributor: altomed pharmaceuticals,inc. - ceftriaxone (as sodium) - powder for injection(i.m./i.v.) - 1 g

European Union - English - EMA (European Medicines Agency)

sloan pharma s.a.r.l - botulinum toxin type b - torticollis - muscle relaxants - neurobloc is indicated for the treatment of cervical dystonia (torticollis).see section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type a.

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.2).,

Australia - English - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - magnesium amino acid chelate,manganese amino acid chelate,pyridoxine hydrochloride,zinc amino acid chelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - zinc oxide - cutaneous cream - 320mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m loveridge ltd - zinc oxide - cutaneous cream - 320mg/1gram